Guardant Health price target raised to $100 from $70 at Stifel

Stifel analyst Daniel Arias raised the firm’s price target on Guardant Health (GH) to $100 from $70 and keeps a Buy rating on the shares. The firm’s Q3 results were “particularly strong,” with a robust top-line and a boost to its FY25 guidance, the analyst tells investors. Stifel believes the ongoing business momentum can support the stock momentum.